Monomethyl lithospermate BCAS# 122021-74-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 122021-74-3 | SDF | Download SDF |
| PubChem ID | 6438135 | Appearance | Powder |
| Formula | C36H28MgO16 | M.Wt | 740.90 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | magnesium;2-[(E)-3-[3-[1-carboxylato-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoate | ||
| SMILES | C1=CC(=C(C=C1CC(C(=O)[O-])OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)[O-])O)O.[Mg+2] | ||
| Standard InChIKey | ANUBYMNVOPVATP-OAZHBLANSA-L | ||
| Standard InChI | InChI=1S/C36H30O16.Mg/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17;/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48);/q;+2/p-2/b10-5+; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Magnesium lithospermate B can protecte cardiomyocytes from ischemic injury through specific inhibition of TAB1-p38 apoptosis signaling. 2. Magnesium lithospermate B is an inhibitor of lipid peroxidation and scavenge superoxide anions and hydroxyl radicals both in vitro and ex vivo. 3. Magnesium lithospermate B can ameliorate cisplatin-induced injury in cultured renal epithelial cells. 4. Magnesium lithospermate B is a naturally occurring, new generation antioxidant that activates eNOS and ameliorates endothelial dysfunction in diabetes by enhancing vasodilation in addition to reducing oxidative stress.[ 5. Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase, it provides anti-ischemic neuroprotection in gerbilssubjected to focal ischemia and reperfusion. 6. Magnesium lithospermate B has protective effects against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway.[6] 7. Magnesium lithospermate B has potent antifibrotic effect in intraperitoneal thioacetamide (TAA)-treated cirrhotic rats, and inhibits fibrogenic responses in hepatic stellate cells (HSCs). 8. Magnesium lithospermate B has depressor action on blood pressure in spontaneously hypertensive rats. 9. Magnesium lithospermate B may stimulate the synthesis of kallikrein and/or conversion to active kallikrein, thus improving renal function. 10.Magnesium lithospermate B has anti-wrinkle and anti-aging effects on skin. |
| Targets | p65 | NF-kB | TGF-β/Smad | ROS | PDGFR |
Monomethyl lithospermate B Dilution Calculator
Monomethyl lithospermate B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3497 mL | 6.7485 mL | 13.4971 mL | 26.9942 mL | 33.7427 mL |
| 5 mM | 0.2699 mL | 1.3497 mL | 2.6994 mL | 5.3988 mL | 6.7485 mL |
| 10 mM | 0.135 mL | 0.6749 mL | 1.3497 mL | 2.6994 mL | 3.3743 mL |
| 50 mM | 0.027 mL | 0.135 mL | 0.2699 mL | 0.5399 mL | 0.6749 mL |
| 100 mM | 0.0135 mL | 0.0675 mL | 0.135 mL | 0.2699 mL | 0.3374 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- PLP (139-151)
Catalog No.:BCC5920
CAS No.:122018-58-0
- Cyhalofop
Catalog No.:BCC5474
CAS No.:122008-78-0
- Niazirin
Catalog No.:BCN7300
CAS No.:122001-32-5
- Sulfamonomethoxine
Catalog No.:BCC9156
CAS No.:1220-83-3
- 3-Phenyl-1-propanol
Catalog No.:BCC8102
CAS No.:122-97-4
- Phenylacetaldehyde
Catalog No.:BCN3819
CAS No.:122-78-1
- Cinnamyl cinnamate
Catalog No.:BCN4722
CAS No.:122-69-0
- (-)-Ampelopsin H
Catalog No.:BCC8842
CAS No.:
- Zingerone
Catalog No.:BCN1192
CAS No.:122-48-5
- Glycerine trioleate
Catalog No.:BCN2287
CAS No.:122-32-7
- Tetraethoxypropane
Catalog No.:BCN2221
CAS No.:122-31-6
- Sulfadimethoxine
Catalog No.:BCC5159
CAS No.:122-11-2
- Khayalenoid E
Catalog No.:BCN6111
CAS No.:1220508-29-1
- [bAla8]-Neurokinin A(4-10)
Catalog No.:BCC7137
CAS No.:122063-01-8
- 2'-O-Acetylsprengerinin C
Catalog No.:BCN6655
CAS No.:1220707-33-4
- Charantadiol A
Catalog No.:BCN3483
CAS No.:1220890-23-2
- 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one
Catalog No.:BCN1602
CAS No.:1220891-22-4
- Auraptenol
Catalog No.:BCN6113
CAS No.:1221-43-8
- 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate
Catalog No.:BCC8575
CAS No.:122111-01-7
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- ER-878898
Catalog No.:BCC8958
CAS No.:122111-11-9
- Acarbose sulfate
Catalog No.:BCC4284
CAS No.:1221158-13-9
- Dehydroborapetoside B
Catalog No.:BCN6601
CAS No.:1221178-16-0
- ML 202
Catalog No.:BCC6306
CAS No.:1221186-52-2
Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats.[Pubmed:21499011]
Exp Mol Med. 2011 Jun 30;43(6):341-9.
Magnesium lithospermate B (MLB) is one of the major active components of Salvia miltiorrhizae. The anti-oxidative effects of Salvia miltiorrhizae have been previously reported. The aim of this study was to investigate the effect of purified MLB on hepatic fibrosis in rats and on the fibrogenic responses in hepatic stellate cells (HSCs). Hepatic fibrosis was induced in rats by intraperitoneal thioacetamide (TAA) injections over a period of 8 or 12 weeks. MLB was orally administered daily by gavage tube. Serum AST and ALT levels in TAA+ MLB group were significantly lower than those in TAA only group at week 8. Hepatic fibrosis was significantly attenuated in TAA+MLB group than in TAA only group at week 8 or 12. Activation of HSCs was also decreased in TAA+MLB group as compared to TAA only group. Hepatic mRNA expression of alpha-smooth muscle actin (alpha-SMA), TGF-beta1, and collagen alpha1(I) was significantly decreased in TAA+MLB group as compared to TAA only group. Incubation with HSCs and MLB (>or=100 muM) for up to 48 h showed no cytotoxicity. MLB suppressed PDGF-induced HSC proliferation. MLB inhibited NF-KappaB transcriptional activation and monocyte chemotactic protein 1 (MCP-1) production in HSCs. MLB strongly suppressed H(2)O(2)-induced reactive oxygen species (ROS) generation in HSCs, and MLB inhibited type I collagen secretion in HSCs. We concluded that MLB has potent antifibrotic effect in TAA-treated cirrhotic rats, and inhibits fibrogenic responses in HSCs. These data suggest that MLB has potential as a novel therapy for hepatic fibrosis.
Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B.[Pubmed:11501171]
Acta Pharmacol Sin. 2000 Sep;21(9):855-8.
AIM: To study the effect of magnesium lithospermate B (MLB) on the lipid peroxidation and on its free radical scavenging activity. METHODS: MLB was incubated in rat tissue homogenate or in a free radical generating system. MLB induced inhibition of lipid peroxidation and its scavenging activity on superoxide anions and hydroxyl radicals was studied using colorimetric estimation. RESULTS: MLB inhibited the lipid peroxidation induced by either an auto-oxidant or Fe2+/VitC in vitro, in the liver homogenate, the inhibitory rate of MLB (10 mg/L) being 69.2% and 57.7%, respectively. MLB (25 and 50 mg/kg) decreased the amount of thiobarbituric acid reactive substances (TBARS) in rat serum, liver, kidney, and heart. However, it did not inhibit the lipid peroxidation of brain homogenate ex vivo. MLB scavenged superoxide anions generated from xanthine/xanthine oxidase system and iron-dependent hydroxyl radicals. CONCLUSION: MLB is an inhibitor of lipid peroxidation and scavenge superoxide anions and hydroxyl radicals both in vitro and ex vivo.
